WO2024157889A1 - 電気泳動により対象物質を処理する方法及び装置 - Google Patents
電気泳動により対象物質を処理する方法及び装置 Download PDFInfo
- Publication number
- WO2024157889A1 WO2024157889A1 PCT/JP2024/001427 JP2024001427W WO2024157889A1 WO 2024157889 A1 WO2024157889 A1 WO 2024157889A1 JP 2024001427 W JP2024001427 W JP 2024001427W WO 2024157889 A1 WO2024157889 A1 WO 2024157889A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- separator
- target substance
- electrophoresis
- chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D57/00—Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C
- B01D57/02—Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C by electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N2001/4038—Concentrating samples electric methods, e.g. electromigration, electrophoresis, ionisation
Definitions
- the present invention relates to a method and apparatus for processing a target substance by electrophoresis.
- Electrophoresis is one such technique.
- Various electrophoretic methods have been developed.
- two-dimensional electrophoresis is a technique in which target substances are separated by electrophoresis in two directions in sequence, and is widely used in protein analysis.
- a polyacrylamide gel is used to separate substances in a linear direction by isoelectric focusing (first dimension), and then the substances are separated at right angles to the first dimension by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) based on molecular weight (second dimension).
- SDS-PAGE SDS-polyacrylamide gel electrophoresis
- second dimension molecular weight
- Dialysis is also a method for separating substances.
- Various dialysis methods have been developed. For example, discontinuous diafiltration involves concentrating the solution by centrifugal ultrafiltration and then diluting it with a buffer to exchange the buffer.
- dialysis generally requires a large device, a large amount of solvent (buffer), and a long processing time (several hours to a full day).
- Centrifugal ultrafiltration is prone to clogging and is not suitable for crude samples that contain a lot of impurities.
- Dialysis is a phenomenon based on osmotic pressure, so the target substance cannot be concentrated as is.
- 50% to 60% glycerol is mixed into the external solution. This causes the water in the internal solution to be expelled into the external solution.
- glycerol enters and is mixed into the internal solution in which the target substance is present. Concentrated glycerol increases the viscosity of the solution. Therefore, the mixed glycerol can affect the analysis or measurement of the target substance contained in the internal solution.
- glycerol is a non-ionic substance and has no charge, it cannot be separated using electrophoresis.
- a method for processing a target material by electrophoresis includes: Providing a separator that allows the passage of the target substance; introducing a first solution containing the substance of interest onto a first side of the separator; introducing a second solution to a second side of the separator; and selectively transferring the target substance from the first solution through the separator to the second solution by electrophoresis; Equipped with.
- an apparatus for processing a target substance by electrophoresis.
- the apparatus comprises: First solution chamber (loading chamber); a second solution chamber (elution chamber) adjacent to the first solution chamber (input chamber); and a separator that separates the first solution chamber from the second solution chamber, allows the passage of a target substance from the first solution chamber to the second solution chamber, and has electrical conductivity; Equipped with the first solution chamber is filled with a first solution containing the target substance; the second solution chamber is filled with a second solution; an electric field is applied from outside the first solution chamber and the second solution chamber to selectively migrate the target substance from the first solution chamber through the separator to the second solution chamber by electrophoresis; It is structured as follows.
- FIG. 1 is a schematic diagram of an electrophoretic device according to an embodiment.
- FIG. 1 is a schematic diagram of an electrophoretic device according to an embodiment.
- FIG. 1 is a schematic diagram of an electrophoretic device according to an embodiment.
- FIG. 1 is a schematic diagram of an electrophoretic device according to an embodiment.
- FIG. 1 is a schematic diagram of an electrophoretic device according to an embodiment.
- 13 is a graph showing the results of concentration rates according to one embodiment.
- FIG. 1 is a schematic diagram of a pipette cartridge including an electrophoresis unit according to one embodiment.
- the substance of interest may be a substance contained in a subject's subject solution.
- the processing of the substance of interest may be subject to testing in the subject.
- the subject may include or be a human. In some embodiments, the subject may include or be a non-human animal. The subject may include or be a mammal. The subject may be, for example, but not limited to, a working animal, a livestock animal, a pet animal, or a wild animal. The subject may be a plant or a microorganism.
- the sample containing the target substance may be a solution.
- the “solution” may be a solution derived from a subject.
- the “solution” may be a body fluid, a solution derived from a body fluid, or a dilution of a body fluid.
- the solution may be a solution that is not a body fluid (non-body fluid-derived), or a mixture of a body fluid or a solution derived from a body fluid and a solution derived from a non-body fluid.
- the solution may be a homogenate of fine objects, cells, extracellular vesicles, etc., a culture medium, etc.
- the solution may be a solution used for sample measurement, or a solution used for calibration measurement.
- the solution may be a standard solution or a calibration solution.
- the solution may be a liquid that does not intentionally or deliberately contain the target substance to be measured in order to be used for calibration, etc.
- the sample to be measured may be a specimen.
- the solution may be a
- the "body fluid” may be lymphatic fluid, tissue fluid such as interstitial fluid, intercellular fluid, or interstitial fluid, or may be body cavity fluid, serous cavity fluid, pleural fluid, peritoneal fluid, pericardial fluid, cerebrospinal fluid, synovial fluid, or aqueous humor.
- the body fluid may be digestive fluid such as saliva, gastric juice, bile, pancreatic juice, or intestinal fluid, or may be sweat, tears, nasal mucus, urine, semen, vaginal fluid, amniotic fluid, or milk.
- the body fluid may be an animal body fluid or a human body fluid.
- the "body fluid” may be a solution.
- the solution may contain a physiological buffer solution such as phosphate buffered saline (PBS) or N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid buffer (TES) that contains the target substance.
- PBS phosphate buffered saline
- TES N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid buffer
- the solution is not particularly limited as long as it contains the target substance.
- the solution may include a target substance.
- the solution may have the potential to include a target substance.
- the target substance may be a molecule, an ion, a polymer, a biomolecule, or the like.
- the target substance may comprise a biomolecule.
- the target substance may be a biological material.
- the target substance may be a protein, a glycated protein, or the like.
- the solution may be tears, and the target substance may be albumin, glycated albumin, hemoglobin, or glycated hemoglobin contained in the tears.
- the target substance may be albumin, glycated albumin, hemoglobin, or glycated hemoglobin in blood, serum, or plasma, or may be albumin, glycated albumin, hemoglobin, or glycated hemoglobin in interstitial fluid, urine, or saliva.
- Albumin may be oxidized albumin (HNA) or reduced albumin (HMA).
- the target substance may be AGEs (Advanced Glycation End Products).
- the target substance may be a glycated lipid.
- albumin includes both glycated (glycoalbumin) and non-glycated albumin, and includes both oxidized and reduced albumin, unless otherwise specified.
- the solution containing the target substance may be a crude sample.
- the term "crude sample” generally refers to a sample of biological origin that is believed to contain the target substance and that has not been subjected to a procedure for isolating or purifying the target substance.
- "Crude sample” does not exclude culture fluids or solutions of microorganisms, cells, extracellular vesicles, etc.
- impurities generally refers to materials that are not the target material to be recovered, regardless of whether they are impurities or contaminants, unless otherwise indicated.
- ⁇ Separator> generally refers to a membrane, member, or region that separates two solutions.
- a separator allows a substance of interest contained in one solution to pass through to the other.
- a separator allows contaminants contained in one solution to pass through to the other and prevents the substance of interest from passing through.
- the expression “separator partitions the solution compartment” or similar expressions means that the amount of permeation (the passage of the solvent through the separator) of the solvent or buffer contained in the solution compartment is sufficiently small relative to the dialysis (the passage of the solute through the separator) of the target substance during the desired separation or other operation. This does not require that no trace permeation occurs at all.
- the separator of the present disclosure preferably has electrical conductivity suitable for electrophoresis.
- the components or materials constituting the separator are not necessarily electrically conductive.
- the expression "the separator divides the solution chamber" or similar expressions used in this specification should be interpreted to the extent that the target substance can pass through the separator during electrophoresis.
- the separator may comprise a gel.
- gels include, but are not limited to, agarose gels, polyacrylamide gels (PAGE), and the like.
- the separator may include filter paper or cellulose.
- the separator may include a resin (e.g., polytetrafluoroethylene (PTFE)).
- PTFE polytetrafluoroethylene
- the separator may include multiple different materials.
- the separator may include a filter paper (such as a cellulose membrane or other membrane) and a gel.
- the gel may be located on the introduction chamber side of the filter paper.
- the filter paper provides physical support for the gel.
- the solvents of the solutions on either side of the separator may be different from each other, in some embodiments, the first buffer in the first solution chamber and the second buffer in the second solution chamber may be different from each other, in which case a buffer exchange is performed on the subject material.
- the solvent of the solution may be a buffer.
- buffers include, but are not limited to, Tris-glycine buffer, phosphate buffer, sodium barbiturate buffer, etc.
- the volumes of the solution chambers or the volumes of the solutions on either side of the separator may be different.
- the volume of the second solution chamber or the amount of the second solution (second buffer) in the second solution chamber is smaller than the volume of the first solution chamber or the amount of the first solution (first buffer) in the first solution chamber. This allows for concentration of the target substance. Not all of the target substance in the first solution chamber (input chamber) is transferred to the second solution chamber (elution chamber) by electrophoresis.
- the volume of the second solution or the second solution chamber, or the properties of the second solution or the second solution chamber may be configured such that the concentration of the target substance in the second solution after electrophoresis is higher than the concentration of the target substance in the initial first solution.
- concentration rate as used in this specification is defined as the ratio C1/C0 of the concentration C0 of the target substance in the first solution chamber (input chamber) before electrophoresis to the concentration C1 of the target substance in the second solution chamber (elution chamber) after electrophoresis.
- a substance that migrates to the first solution chamber by electrophoresis may be added to the second solution.
- the counter substance preferably has an opposite charge to the target substance in solution. Examples of counter substances include, but are not limited to, biopolymers such as proteins and artificial polymers.
- the separator may be selective, i.e., the separator may have the ability to pass a molecule of interest and not allow, inhibit, or block the passage of other molecules of interest or contaminants.
- the separator may be or include a semipermeable or dialysis membrane.
- the semipermeable or dialysis membrane may be selected from cellulose esters, regenerated cellulose, and the like.
- the separator may be chemically selective. In some embodiments, the separator may allow the passage of contaminants.
- the separator may include a substance that provides selective electrophoresis (sometimes referred to herein as a "selective substance").
- the separator may include a substance that has the ability to purify proteins.
- the separator may include a resin for protein purification.
- the separator may be selected from hydroxyapatite, a cation exchange carrier, an anion exchange carrier, and the like. Hydroxyapatite may be either Type I or Type II. Examples of hydrophobic resins include compounds having butyl groups, phenyl groups, hexyl groups, and the like as functional groups.
- the separator may include a compound or mixture having functional groups that exhibit multiple different interactions (ion exchange, hydrophobic bonds, affinity bonds, and the like).
- the separator may include a compound used in a mixed mode. These substances suppress, do not allow, or block the passage of impurities. This allows the degree of purification of the target substance to be increased, for example, compared to when no resin is included.
- the selective substance may be contained in or supported by a gel.
- the selective substance may be supported on or near the surface of a semipermeable membrane.
- the selective substance may be disposed in a portion other than the separator.
- the selective substance may be provided in the first solution or in the first solution chamber.
- the selective substance may be mixed into the first solution prior to electrophoresis.
- a first solution chamber, a second solution chamber, a third solution chamber, a first separator between the first solution chamber and the second solution chamber, and a second separator between the second solution chamber and the third solution chamber may be provided.
- the electrode pair may be disposed outside the first solution chamber and the third solution chamber.
- the first separator allows the target substance to pass through, and the second separator does not allow the target substance to pass through.
- the second separator may not allow the target substance to pass through, but may allow some of the impurities (e.g., substances smaller than the target substance) to pass through. As a result, the target substance moves from the first solution chamber through the first separator to the second solution chamber and is retained there.
- the impurities are retained in the first solution chamber. Another part of the impurities passes through the second solution chamber and the second separator and enters the third solution chamber. This allows, for example, further purification of the target substance to be performed.
- two or more separators may be used.
- three or more solution chambers or solutions may be used.
- the target material that has been subjected to electrophoretic processing may be transferred to another location (collection chamber, sensor, chamber for performing another process, etc.) by further electrophoresis.
- electrophoresis may move the treated target substance to a sensor for detection.
- the device may further include a sensor.
- the device may be configured to be coupled to a sensor.
- the third solution chamber may be a space in which a sensor for detecting the target substance is disposed.
- a solution containing a target substance can be introduced into such a sensing device, electrophoretic processing (separation, purification, buffer exchange, concentration, etc.) can be performed, and the processed target substance can be detected by the sensing device.
- electrophoretic processing separation, purification, buffer exchange, concentration, etc.
- the processed target substance can be detected by the sensing device.
- selectivity for the target substance and the impurities may be generated depending on the pH of the input solution.
- the pH of the input solution may be set to be between the isoelectric points of the target substance and the impurities. For example, when the target substance, which is negatively charged in the input solution, is attracted to the positive electrode, the pH of the input solution is set to be higher than the isoelectric point of the target substance. The surface of the target substance is negatively charged and attracted to the positive electrode.
- the pH of the input solution may be set so that the isoelectric point of the target molecule in the input solution is smaller than that and higher than the isoelectric point of the impurities.
- the impurities may move in the opposite direction to the target substance. For example, even if the impurities move to the same electrode, the amount of movement may be sufficiently small compared to the target substance. For example, the impurities may not move. This allows purification or separation of the target substance.
- multiple processes such as buffer exchange, concentration, purification, and separation may be performed simultaneously.
- the multiple processes may be selected from the group consisting of buffer exchange, concentration, purification, and separation.
- the multiple processes may or may not overlap with each other.
- the expression “multiple processes are performed simultaneously” means that multiple processes are performed during one one-dimensional electrophoresis process, unless otherwise specified.
- Some embodiments of the present disclosure do not preclude performing two-dimensional or multiple-dimensional electrophoresis. Any one-dimensional electrophoresis may perform the processing electrophoresis of any embodiment of the present disclosure. In some embodiments, multiple dimensions of processing electrophoresis may be performed.
- a process electrophoresis may be performed intermittently.
- the positive and negative electrodes may be switched periodically or irregularly. This may, for example, reduce problems such as separator clogging and/or allow for efficient or effective process electrophoresis.
- Such switching of the electric field direction should not be considered multi-dimensional electrophoresis.
- a series of electrophoretic processes performed with the same electrode pair is considered to be one-dimensional electrophoresis.
- FIG. 1 is used to describe an apparatus 100 and its operation according to one embodiment of the present disclosure.
- the electrophoresis device 100 includes a first solution chamber (input chamber) 101, a second solution chamber (elution chamber) 102 adjacent thereto, and a separator 111 that separates the first solution chamber 101 from the second solution chamber 102.
- a first buffer 131 and a target molecule 141 are input into the first solution chamber 101.
- the second solution chamber 102 is filled with a second buffer 132.
- the electrophoresis device 100 shown in FIG. 1 further includes an electrode pair 121, 122.
- the electrode pair 121, 122 are disposed between the first solution chamber 101 and the second solution chamber 102.
- the electrode pair 121, 122 are disposed so that the target molecule 141 in the first solution chamber 101 moves from the first solution chamber 101 to the second solution chamber 102 through the separator 111 under an electric field generated by the electrode pair 121, 122.
- the electrode pair 121, 122 is connected to a DC power supply 123.
- the switch 125 is open.
- switch 125 is closed to charge electrode 121 negatively and electrode 122 positively, generating an electric field between them. Under this electric field, electrophoresis occurs. That is, the negatively charged target molecule 141 begins to move in the first buffer 131 toward electrode 122. The target molecule 141 passes through separator 111 and enters second buffer 132 in second solution chamber 102.
- electrophoresis is performed for a predetermined time until a sufficient amount of target molecules 141 enters the second buffer 132 in the second solution chamber 102.
- the switch 125 is opened to release the electric field and complete the process.
- the target molecule 141 that was originally contained in the first buffer 131 is now contained in the second buffer 132.
- a buffer exchange has occurred.
- the concentration of the target molecule 141 can be increased.
- FIG. 2 illustrates an apparatus 200 and its operation according to one embodiment of the present disclosure.
- an electrophoresis device 200 includes a first solution chamber (input chamber) 201, an adjacent second solution chamber (elution chamber) 202, and a separator 211 that separates the first solution chamber 201 from the second solution chamber 202.
- a first buffer 231, a target molecule 241, and impurities 242 are input into the first solution chamber 201.
- the second solution chamber 202 is filled with a second buffer 232.
- the electrophoresis device 200 shown in FIG. 2 further includes electrode pairs 221 and 222.
- the switch 225 is open.
- the target molecule 241 and the impurities 242 have different isoelectric points.
- the pH of the first buffer 231 is between these isoelectric points. That is, the isoelectric point of the target molecule 241 is lower than the pH of the first buffer 231, and the isoelectric point of the impurities 242 is higher than the pH of the first buffer 231.
- switch 225 is closed to charge electrode 221 negatively and electrode 222 positively, generating an electric field between them. Under this electric field, electrophoresis occurs. That is, negatively charged target molecule 241 starts to move in first buffer 231 toward electrode 222. Target molecule 241 passes through separator 211 and enters second buffer 232 of second solution chamber 202. Meanwhile, positively charged impurities 242 start to move in first buffer 231 toward electrode 221. In other words, impurities 242 do not move toward electrode 222 or separator 211.
- electrophoresis is performed for a predetermined time, and a sufficient amount of target molecules 241 enters the second buffer 232 in the second solution chamber 202. Impurities 242 remain in the first solution chamber (input chamber) 201 or the first buffer 231.
- the switch 225 is opened to release the electric field and complete the process.
- the target molecule 241 that was originally contained in the first buffer 231 is now contained in the second buffer 232.
- the second buffer 232 does not contain the impurities 242.
- the target molecule 241 has been purified or separated.
- the buffer has been exchanged.
- the concentration of the target molecule 241 can be further increased.
- FIG. 3 illustrates an apparatus 300 and its operation according to one embodiment of the present disclosure.
- the electrophoresis device 300 includes a first solution chamber (input chamber) 301, an adjacent second solution chamber (elution chamber) 302, and a separator 311 that separates the first solution chamber 301 from the second solution chamber 302.
- a first buffer 331, a target molecule 341, and impurities 342 are input into the first solution chamber 301.
- the second solution chamber 302 is filled with a second buffer 332.
- the electrophoresis device 300 shown in Fig. 3 further includes electrode pairs 321 and 322.
- a switch 325 is open.
- the separator 311 has selectivity. That is, the separator 311 has the ability to pass the target molecule 341 and not the impurities 342. For example, it is assumed that the typical impurities 342 have a larger size than the target molecule 341.
- the separator 311 is a semipermeable membrane, and its pore size is larger than the target molecule 341 and smaller than the impurities 342.
- the switch 325 is closed to charge the electrode 321 negatively and the electrode 322 positively, generating an electric field between them. Under this electric field, electrophoresis occurs. That is, the target molecule 341 starts to move in the first buffer 331 toward the electrode 322. The target molecule 341 passes through the separator 311 and enters the second buffer 332 of the second solution chamber 302. In FIG. 3, it is assumed that the impurities 342 have the same charge as the target molecule 341. The impurities 342 start to move in the first buffer 331 toward the electrode 322. However, they cannot pass through the separator 311 and cannot enter the second buffer 332 of the second solution chamber 302, and therefore remain in the first buffer 331.
- electrophoresis is performed for a predetermined time, and a sufficient amount of target molecules 341 enters the second buffer 332 in the second solution chamber 302. Impurities 342 remain in the first solution chamber (input chamber) 301 or the first buffer 331.
- the switch 325 is opened to release the electric field and complete the process.
- the target molecule 341 that was originally contained in the first buffer 331 is now contained in the second buffer 332.
- the second buffer 332 does not contain the impurities 342.
- the target molecule 341 has been purified or separated.
- the buffer has been exchanged.
- the concentration of the target molecule 341 can be further increased.
- FIG. 4 illustrates an apparatus 400 and its operation according to one embodiment of the present disclosure.
- an electrophoresis device 400 includes a first solution chamber (input chamber) 401, an adjacent second solution chamber (elution chamber) 402, and a first separator 411 that separates the first solution chamber 401 from the second solution chamber 402.
- a first buffer 431, a target molecule 441, and impurities 442 and 443 are input into the first solution chamber 401.
- the second solution chamber 402 is filled with a second buffer 432.
- the electrophoresis device 400 further includes a third solution chamber 403 (discharge chamber) adjacent to the second solution chamber (elution chamber) 402, and a second separator 412 that separates the second solution chamber 402 from the third solution chamber 403.
- a third solution chamber 403 discharge chamber
- second solution chamber elution chamber
- second separator 412 that separates the second solution chamber 402 from the third solution chamber 403.
- the electrophoresis device 400 in FIG. 4 further includes electrode pairs 421 and 422. In FIG. 4A, the switch 425 is open.
- the first separator 411 and the second separator 412 have selectivity. That is, the first separator 411 has the ability to pass the target molecule 441 and not the impurities 442. For example, it is assumed that the typical impurities 442 have a larger size than the target molecule 441.
- the first separator 411 is a semipermeable membrane, and its pore size is larger than the target molecule 441 and smaller than the impurities 442.
- the impurities 443 can pass through the first separator 411.
- the second separator 412 has the ability to pass the impurities 443 and not the target molecules 441.
- the typical impurities 443 have a size smaller than the target molecules 441.
- the second separator 412 is a semipermeable membrane, and the pore size is smaller than the target molecules 441 and larger than the impurities 443.
- the impurities 443 can pass through the first separator 411.
- switch 425 is closed to charge electrode 421 negatively and electrode 422 positively, generating an electric field between them. Under this electric field, electrophoresis occurs. That is, target molecule 441 and impurities 442 and 443 having the same charge begin to move in first buffer 431 toward electrode 422.
- Target molecule 441 and impurities 443 pass through first separator 411 and enter second buffer 432 of second solution chamber 402. Impurities 442 cannot pass through first separator 411 and cannot enter second buffer 432 of second solution chamber 402, and therefore remain in first buffer 431.
- the target molecule 441 and impurities 443 move through the second buffer 432 toward the electrode 422.
- the impurities 443 pass through the second separator 412 and enter the third buffer 433 of the third solution chamber 403.
- the target molecule 441 cannot pass through the second separator 412 and cannot enter the third buffer 433 of the third solution chamber 403, and therefore remains in the second buffer 432.
- electrophoresis is performed for a predetermined time, and a sufficient amount of target molecules 441 enters the second buffer 432 of the second solution chamber 402. Impurities 442 remain in the first solution chamber (input chamber) 401 or the first buffer 431, and impurities 443 enter the third solution chamber (output chamber) 403 or the third buffer 433. Switch 425 is opened to initiate the electric field and complete the process.
- the target molecule 441 that was originally contained in the first buffer 431 is now contained in the second buffer 432.
- the second buffer 432 does not contain the impurities 442, 443.
- the target molecule 441 has been purified or separated.
- the buffer has been exchanged.
- the concentration of the target molecule 441 can be further increased.
- FIG. 5 illustrates an apparatus 500 and its operation according to one embodiment of the present disclosure.
- an electrophoresis device 500 includes a first solution chamber (input chamber) 501, an adjacent second solution chamber (first elution chamber) 502, and a first separator 511 that separates the first solution chamber 501 from the second solution chamber 502.
- a first buffer 531 and a target molecule 541 are input into the first solution chamber 501.
- the second solution chamber 502 is filled with a second buffer 532.
- the electrophoresis device 500 further includes a third solution chamber 503 (second elution chamber) adjacent to the second solution chamber (elution chamber) 502, and a second separator 512 that separates the second solution chamber 502 from the third solution chamber 503.
- the third solution chamber 503 is filled with a second buffer 533.
- Electrophoresis device 500 in FIG. 5 further includes a first electrode pair 521a, 522a, and is arranged to perform electrophoresis on first solution chamber 501, first separator 511, and second solution chamber 502.
- the second separator and third solution chamber are arranged perpendicular or at an angle to the electric field generated by first electrode pair 521a, 522a.
- Electrophoresis device 500 in FIG. 5 further includes a second electrode pair 521b, 522b, and is arranged to perform electrophoresis on second solution chamber 502, second separator 512, and third solution chamber 503.
- the first solution chamber 501, the first separator 511, the second solution chamber 502, and the first electrode pair 521a, 522a may be configured to perform a primary electrophoresis
- the second solution chamber 502, the second separator 512, the third solution chamber 503, and the second electrode pair 521b, 522b may be configured to perform a secondary electrophoresis.
- the switches are omitted.
- the target molecule 541 begins to move in the first buffer 531 toward the electrode 522a.
- the target molecule 541 passes through the first separator 511 and enters the second buffer 532 of the second solution chamber 502.
- Electrophoresis is carried out for a predetermined time until a sufficient amount of target molecules 541 enters the second buffer 532 in the second solution chamber 502. The electric field is released to complete the primary electrophoresis.
- the target molecule 541 that was originally contained in the first buffer 531 is now contained in the second buffer 532.
- a buffer exchange has occurred.
- the concentration of the target molecule 541 can be increased.
- the voltage on the first electrode pair 521a, 522a is released, and a voltage is applied to the second electrode pair 521b, 522b to generate an electric field between them. Under this electric field, electrophoresis occurs. That is, the target molecule 541 begins to move in the second buffer 532 toward the electrode 522b. The target molecule 541 passes through the second separator 512 and enters the third buffer 533 of the third solution chamber 503.
- Electrophoresis is carried out for a predetermined time until a sufficient amount of target molecules 541 enters the third buffer 533 in the third solution chamber 503. The electric field is released to complete the secondary electrophoresis.
- the target molecule 541 that was initially contained in the first buffer 531 is now contained in the third buffer 533 via the second buffer 532. Two buffer exchanges have been performed. In some embodiments, the concentration of the target molecule 541 can be further increased.
- separation or purification may be performed by primary electrophoresis and secondary electrophoresis. In some embodiments, separation or purification may be performed primarily by primary electrophoresis and not secondary electrophoresis. In some embodiments, concentration may be performed by primary electrophoresis and secondary electrophoresis. In some embodiments, concentration may be performed primarily by primary electrophoresis and not secondary electrophoresis. In some embodiments, buffer exchange may be performed by primary electrophoresis and secondary electrophoresis. In some embodiments, buffer exchange may be performed primarily by primary electrophoresis and not secondary electrophoresis.
- the primary electrophoresis may perform one or more of the following processes on the target molecules contained in the input liquid: separation, purification, concentration, and buffer exchange, and the secondary electrophoresis may move the processed target molecules to another location.
- the secondary electrophoresis may move the processed target molecules to a location such as a system, sensor, flow path, or space that measures the target molecules.
- the third solution chamber in this embodiment may be a solution chamber for a system, sensor, flow path, or space that measures the target molecules, or may be a solution chamber fluidically connected to them.
- the contaminants may be allowed to pass through a separator while preventing the target material from passing through the separator.
- another substance may be bound to the target substance or impurities.
- the binding substance may be designed or selected such that a complex of the target substance or impurities and the binding substance cannot pass through a size-selective separator.
- the binding substance may be designed or selected such that the isoelectric point of the complex of the binding substance and the target substance is different from the isoelectric point of the target substance.
- the target substance may be designed so that it does not migrate alone, but the complex with the binding substance does, or vice versa.
- the device may include an input chamber and two adjacent elution chambers.
- a first elution chamber, a first separator, an input chamber, a second separator, and a second elution chamber may be arranged in this order between the electrode pair in the direction of the electric field.
- a first target substance may move from the input chamber through the first separator to the first elution chamber
- a second target substance may move from the input chamber through the second separator to the second elution chamber.
- the pH of the input liquid may be set to be between the isoelectric points of the first target substance and the second target substance.
- the direction of the electric field may be reversed.
- application of a unidirectional electric field may cause the target substance to move and some of the impurities (e.g., small molecules) to move to the elution chamber.
- impurities e.g., small molecules
- Application of a reverse electric field causes the target substance and small molecules that have moved to the elution chamber to move again toward the input chamber.
- small molecules with a smaller molecular weight than the target substance move faster than the target substance and can return to the input chamber.
- the target substance does not move as quickly as the small molecules and cannot return to the input chamber.
- application of an appropriate reverse electric field in addition to application of a positive electric field can promote the reverse movement of the impurities from the target substance, thereby increasing the concentration and/or purity of the target substance in the elution chamber.
- HSA Human serum albumin
- Wako Tris-glycine buffer
- DW pure water
- ⁇ Preparation of process electrophoresis tubes For the process electrophoresis, a plastic tube with an inner diameter of about 6 to 8 mm and a length of several cm was used. When two solution chambers were provided, two interfittable tubes (an input chamber tube and an elution chamber tube) were used. These were tightly connected, and a separator or a membrane supporting the separator was tightly sandwiched between them. When a semipermeable membrane was used as the separator, the semipermeable membrane was tightly sandwiched between the two tubes.
- a 0.45 ⁇ m polytetrafluoroethylene resin coating membrane (PTFE membrane) or a 0.2 ⁇ m cellulose acetate membrane was used as a support for the gel and tightly sandwiched between the two tubes, and a liquid gel was dropped onto the surface of the input chamber and allowed to stand until it solidified.
- PTFE membrane polytetrafluoroethylene resin coating membrane
- a liquid gel was dropped onto the surface of the input chamber and allowed to stand until it solidified.
- Saran Wrap registered trademark, Asahi Kasei Corporation
- a solution containing the target substance is placed in the input chamber, and a buffer solution (Tris-glycine, pH 8.3-9.0) is placed in the elution chamber. After the solution is placed in each end of the tube, they are sealed with a dialysis membrane with a molecular weight cutoff of 12-14 kDa to prevent air bubbles from entering.
- the volume of the elution chamber V1 is adjusted according to the length of the elution chamber, and is approximately 35 ⁇ L to 260 ⁇ L.
- the buffer solution in the elution chamber is Tris-glycine buffer solution (Wako, #201-18601, pH 8.3-9.0).
- Electrophoresis The electrophoresis tube filled with the solution was immersed in an electrophoresis tank filled with 1x Tris-glycine buffer. This was placed in a chromatography chamber maintained at 4°C and kept in a sufficiently cold state. In the electrophoresis tank, the positive electrode was placed at the end of the elution chamber of the electrophoresis tube, and the negative electrode was placed at the end of the input chamber. 150V was applied to these electrodes for 120 minutes.
- DM-JACK registered trademark, Minaris Medical Co., Ltd.
- a calibration curve was prepared using a standard substance as necessary.
- the pre-electrophoresis sample and the eluted sample were diluted with 1x Tris-glycine buffer so that the estimated absorbance was approximately within the range of the calibration curve.
- Electrophoresis for measurement was performed using SDS-PAGE. After process electrophoresis, the eluate was removed from the elution chamber. In the case of saliva samples, 30 ⁇ L of eluate was mixed with 10 ⁇ L of 4 ⁇ Loading Buffer (Wako, #196-16142). In the case of serum samples, 5 ⁇ L of eluate diluted 25 to 50 times was mixed with 5 ⁇ L of 4 ⁇ Loading Buffer (Wako, #196-16142) and 10 ⁇ L of DW. The sample was heated at 95° C. for 10 minutes. Next, 8 ⁇ L was dropped onto a 10% polyacrylamide gel (DRC, #NTH-525P). Electrophoresis was performed at 180 V for 60 minutes, and then stained, decolorized, and photographed.
- DRC 10% polyacrylamide gel
- Example 1 Concentration Ideally, if all molecules of the target substance initially loaded into the loading chamber move to the elution chamber, the ratio (V1/V0) of the volume of the loading chamber (V0) to the volume of the elution chamber (V1) becomes the concentration rate (C1/C0).
- the target substance may adhere to the separator and the inner wall of the loading chamber.
- some of the target substances may not be able to pass through the separator within a preset time. For example, some of the target substances may leak out of the electrophoresis tube.
- the concentration rate can be considered to be a function of the ratio of the volumes of the loading chamber and the elution chamber.
- V0/V1 6 to 56
- HSA albumin
- the HSA added was prepared at two concentrations: 5x dilution and 20x dilution.
- agarose gel was used as a separator.
- the concentration of each HSA was determined by absorbance method using DM-JACK.
- the concentration rate was calculated as the ratio of the concentration (C0) before addition (before process electrophoresis) to the concentration (C1) after process electrophoresis (obtained from the elution chamber).
- the concentration ratio was observed to be approximately linear with respect to the volume ratio. Not all of the albumin in the input solution was transferred to the elution chamber. However, this linear relationship indicates that the concentration ratio can be easily determined or controlled by the structure of the electrophoresis device.
- Example 2 Purification using agarose gel
- agarose gel was used as a separator to purify albumin as a target substance from saliva and serum.
- the saliva sample was prepared as follows: 3.6 mL of saliva sample was obtained from the inventor and filtered through cotton. This was mixed with 0.4 mL of 1x Tris-glycine buffer (Wako, #201-18601, pH 8.3-8.9). The serum sample was prepared in the same manner as in Example 1.
- the separator was made by dissolving agarose gel in 1x Tris-glycine buffer (both from Wako) at a volume ratio of 1%. This was supported by a filter unit made of Ultrafree MC-HV PVDF ⁇ 0.45 ⁇ m (Merck).
- Process electrophoresis was performed for 240 minutes with an applied voltage of 100V.
- Figure 7 shows the electrophoretic gel photograph. 1 and 2 respectively correspond to the original saliva sample and the eluate after process electrophoresis. 3 and 4 respectively correspond to the original serum sample and the eluate after process electrophoresis. Albumin is indicated by the black arrow, and the main impurities are indicated by the white arrow.
- the target substance, albumin was concentrated and contaminants were removed in both saliva and serum samples.
- Example 3 Purification using polyacrylamide gel
- polyacrylamide gel was used as a separator to purify albumin as a target substance from serum.
- Serum samples were prepared by mixing 0.6 mL of serum (Cosmo Bio, #12181450), 0.6 mL of 1x Tris-glycine buffer (pH 8.5), and 4.8 mL of ultrapure water (DW).
- the separator was prepared as follows. First, a 9% polyacrylamide gel was prepared by mixing 300 ⁇ L of ultrapure water, 50 ⁇ L of 1x Tris-glycine pH 8.5, 150 ⁇ L of 30 w/v% acrylamide/bis mixture, 2.5 ⁇ L of 10% APS, and 0.25 ⁇ L of TMED. This gel was placed in an elution chamber tube with one end closed with Saran Wrap. After solidification, the Saran Wrap was removed and the elution chamber tube was connected to the input chamber tube.
- Process electrophoresis was performed for 150 minutes with an applied voltage of 150 V.
- Measurement electrophoresis was performed as follows. First, after process electrophoresis, the eluate was removed from the elution chamber. 1 ⁇ L of the eluate, which had been diluted 25-fold with 1 ⁇ Tris-glycine buffer (pH 8.5), was mixed with 5 ⁇ L of 4 ⁇ Loading Buffer (Wako, #196-16142) and 14 ⁇ L of ultrapure water. 5 ⁇ L of the original serum sample, which had been diluted 25-fold, was mixed with 5 ⁇ L of 4 ⁇ Loading Buffer (Wako, #196-16142) and 10 ⁇ L of ultrapure water. The mixture was heated at 95°C for 10 minutes. 8 ⁇ L of the mixture was dropped onto a 10% polyacrylamide gel (DRC, #NTH-525P). Electrophoresis was performed on this at 180 V for 60 minutes.
- Figure 8 shows a photograph of the electrophoresis gel. 1 and 2 correspond to the original serum sample and the eluate after process electrophoresis, respectively.
- the albumin band (black arrow) in the serum sample (2) after process electrophoresis was darker and the band of impurities (white arrow) was extremely faint. Based on the intensity of the bands, the concentration rate of this process electrophoresis was approximately 6.5 times. In other words, the impurities were removed and the target substance, albumin, was concentrated.
- Example 4 Purification using a dialysis membrane
- a dialysis membrane (semipermeable membrane) was used as a separator to purify albumin as a target substance from serum.
- Serum samples were prepared in the same manner as in Example 3.
- a 100 kDa dialysis membrane (Biotech CE, trial kit, 100 KD, 24 mm, 1 m (131417T)) was used as a separator.
- Process electrophoresis was performed for 120 minutes with an applied voltage of 150V.
- Measurement electrophoresis was performed as follows. First, after process electrophoresis, the eluate was removed from the elution chamber and diluted 25-fold with 1x Tris-glycine buffer (pH 8.6). 5 ⁇ L of the 10x diluted eluate, 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142), and 10 ⁇ L of DW were mixed. The mixture was heated at 95°C for 10 minutes. 1 ⁇ L, 4 ⁇ L, or 8 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was performed at 180 V for 60 minutes.
- Figure 9 shows a photograph of the electrophoresis gel. 1 and 2 correspond to the original serum sample and the eluate after process electrophoresis, respectively.
- the albumin band (black arrow) is darker and the impurity band (white arrow) has almost disappeared.
- the molecular weight of HSA is approximately 66 kDa.
- Process electrophoresis confirmed that HSA smaller than 100 kDa passed through the separator, while molecules larger than this did not. Molecules larger than 100 kDa are contained in serum but not in saliva. Amylase is contained in saliva but not in serum.
- Example 5 Purification based on isoelectric point
- Separators were prepared by introducing 1% agarose gel into 10 mM sodium phosphate buffer, 1x Tris-glycine buffer (pH 6.5), or 1x Tris-glycine buffer (pH 8.5). 250 ⁇ L of this gel was supported using a Gel Ultrafree MC-HV PVDF ⁇ 0.45 ⁇ m (Merck) filter unit.
- Process electrophoresis was performed at 130 mA for 140 minutes.
- Measurement electrophoresis was performed as follows. First, after process electrophoresis, the eluate was removed from the elution chamber. 0.8 ⁇ L of the eluate was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142), and 14.2 ⁇ L of DW. 4 ⁇ L of the original mixed sample solution was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142), and 11 ⁇ L of DW. The mixture was heated at 95°C for 10 minutes. 5 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was performed on this at 180 V for 60 minutes.
- Figure 10 shows an electrophoretic gel photograph.
- 1 and 2 correspond to the original sample (1) and the eluate (2) after process electrophoresis when the input solution had a pH of 8.5.
- 3, 4, and 5 correspond to the original sample (3), the eluate (4) after process electrophoresis, and the eluate (5) after reverse process electrophoresis when the input solution had a pH of 6.5.
- Example 6 Addition of resin
- a resin was added to the separator, and albumin, a target substance, was purified from saliva.
- Saliva samples were prepared as follows: 12.6 mL of saliva was obtained from the inventor and filtered through cotton. This was mixed with 1.4 mL of 1x Tris-glycine buffer (pH 7.5).
- each resin was added to this. The addition was carried out as follows. First, the additives were equilibrated with 1x Tris-glycine buffer and as much of the supernatant as possible was removed. 2% agarose gel dissolved in each resin kept at 65°C was added and mixed. The resin and agarose gel were thoroughly suspended, and about 250 ⁇ L of this was introduced into the separator section and allowed to cool sufficiently to solidify. A cellulose acetate membrane filter ⁇ 0.2 ⁇ m (Advantec Toyo) was used to support the agarose mixed gel.
- Cation exchange carrier TOYOPEARL SP-650M, TOSOH, #0007997
- Anion exchange carrier TOYOPEARL SuperQ-650M, TOSOH, #0017227 Hydroxyapatite
- HA CHT Ceramic Hydroxyapatite, Bio-Rad, #1582200
- Process electrophoresis was performed at 130 mA for 120 minutes.
- the measurement electrophoresis was carried out as follows. First, after process electrophoresis, the eluate was removed from the elution chamber. 10 ⁇ L of the eluate was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142) and 5 ⁇ L of DW. The mixture was heated at 95°C for 10 minutes. 3 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was carried out at 180 V for 60 minutes.
- Figure 11 shows electrophoretic gel images of additives SP and HA. 1, 2, 3, and 4 correspond to the original saliva sample (1), the eluate without resin additive (2), the eluate with SP added (3), and the eluate with HA added (4), respectively.
- Figure 12 shows an electrophoretic gel photograph of additive SQ. 1, 2, and 3 correspond to the original saliva sample (1), the eluate without resin additive (2), and the eluate with SQ added (3), respectively.
- the albumin band was almost the same as or slightly fainter than in the eluate without resin additive (2), and the amylase band had almost disappeared. It was found that SQ very effectively blocks the passage of amylase into the elution chamber.
- the ratio of HSA and the two amylases present in each solution was determined from the intensity of the bands in the electrophoresis gel photographs shown in Figures 11 and 12 ( Figure 13).
- "Amylase_up” and “Amylase_down” correspond to the two bands that appear below the albumin peak, with “Amylase_up” referring to the band close to albumin and “Amylase_down” referring to the band far from albumin.
- the solutions shown here are the original saliva, the eluate after process electrophoresis without a resin additive, and the eluate after process electrophoresis when additives SP, HA or SQ were added.
- Figure 13 shows a graph summarizing the results of Figures 11 and 12.
- the original saliva contains a very large amount of amylase relative to HSA.
- HSA and two amylases are compared.
- Amylase_down is high (A).
- albumin is concentrated, and amylase remains unchanged, becoming relatively low relative to albumin (B).
- B shows the concentration rate and impurity removal rate in the absence of resin additive.
- C-E concentration rate and impurity removal rate in the absence of resin additive.
- C-E impurities
- Example 7 Improvement of concentration rate
- agarose gel was used as a separator, a counter substance was added to the eluate in advance, and albumin, which was the target substance, was concentrated from the serum sample.
- a 20-fold dilution of HSA was prepared as a serum sample. 100 ⁇ L of 1% agarose was used as a separator. A cellulose acetate membrane filter ⁇ 0.2 ⁇ m (Advantec Toyo) was used to support the agarose mixed gel.
- the counter materials used in this example are as follows: RNase A (MACHEREY-NAGEL). A protein with a molecular weight of 13.7 kDa or less and an isoelectric point of 8.6. Lysozyme (derived from egg white) (Nacalai Tesque, Inc.). 14 kDa enzyme, isoelectric point 11. Each of these has an opposite charge to albumin and moves in the opposite direction to albumin during electrophoresis. These were added at various concentrations to the Tris-glycine buffer solution, which was used as the eluent.
- Process electrophoresis was performed at 150V for 240 minutes.
- the eluate was removed from the elution chamber and subjected to measurement electrophoresis.
- the concentration of each albumin was calculated from the density of the albumin band in the electrophoretic bell photograph.
- Figure 14 shows the relationship between the concentration of the counter substance in the initial eluate and the concentration of albumin in the eluate after process electrophoresis when the counter substance is lysozyme (A) and RNase A (B).
- the concentration of albumin in the eluate increased almost in proportion to the concentration of the counter substance.
- the movement of albumin increased the concentration of albumin in the eluate and decreased the concentration of albumin in the input solution, resulting in a decrease in osmotic pressure. This means that there is a limit to the albumin concentration in the eluate.
- Example 8 Separation and concentration of albumin in saliva
- polyacrylamide gel was used as a separator to purify and concentrate albumin as a target substance from saliva.
- the electrophoresis buffer was a tris-glycine buffer (pH 6.0, hereafter referred to as 1x "TMG buffer") whose pH had been adjusted with maleic acid. This 1x TMG buffer was introduced into the elution chamber.
- the saliva samples were prepared as follows: Saliva was obtained from the inventor and filtered through cotton. After filtration, 6 mL of the filtered saliva was mixed with 600 ⁇ L of 10-fold diluted TMG buffer (10x TMG buffer), and 2.5 mL of each was introduced into the input chamber.
- the separator was prepared as follows. First, 114 ⁇ L of ultrapure water, 20 ⁇ L of 1x TMG buffer pH 6.0, 66 ⁇ L of 30 w/v% acrylamide/bis mixture, 2 ⁇ L of 10% APS, and 0.8 ⁇ L of TMED were mixed to prepare a 10% polyacrylamide gel. 160 ⁇ L of this gel was supported using a CELLLOSE ACETATE ⁇ 0.2 ⁇ m (ADVANTEC) filter unit.
- ADVANTEC CELLLOSE ACETATE ⁇ 0.2 ⁇ m
- the measurement electrophoresis was carried out as follows. First, after process electrophoresis, the eluate was removed from the elution chamber, and 15 ⁇ L of the eluate was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142). The mixture was heated at 95°C for 10 minutes. 6 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was carried out at 180 V for 60 minutes.
- Figure 15 shows a photograph of the electrophoretic gel. 1, 2, and 3 respectively correspond to the original saliva sample (1), and the input liquid (2) and eluate (3) after process electrophoresis. Although some amylase (1) that was present in the saliva was detected in the eluate (3), most of it remained in the input chamber (2). In contrast, most of the albumin was able to be transferred to the eluate (3). In this way, it was confirmed that the albumin in the saliva was at least separated from the amylase.
- the intensity of the albumin band in the eluate after process electrophoresis was approximately 12.7 times that in the saliva sample before process electrophoresis. In other words, this process electrophoresis enabled albumin to be concentrated 12.7 times.
- the capacity of the input chamber was 2.5 mL
- the capacity of the elution chamber was 150 ⁇ L
- the ratio is 17 times if osmotic pressure is not taken into account at all. Therefore, this result shows that albumin can be concentrated to a high concentration using this method.
- Example 9 Separation of salivary albumin and macromolecules
- polyacrylamide gel was used as a separator to purify albumin as a target substance from saliva and separate it from macromolecules in the saliva.
- the electrophoresis buffer and saliva sample were the same as those used in Example 8.
- the pH of the eluent and separator gel was adjusted to 8.5.
- the separator was prepared by adding 50 ⁇ L of 1.5% agarose gel and solidifying it to form a support. 110 ⁇ L of a mixture of 10% polyacrylamide gel and 1x TMG buffer (pH 8.5) was then added and allowed to stand at 30°C for 20 minutes.
- the measurement electrophoresis was carried out as follows. First, after process electrophoresis, the eluate was removed from the elution chamber, and 15 ⁇ L of the eluate was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142). The mixture was heated at 95°C for 10 minutes. 3 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was carried out at 180 V for 60 minutes.
- Figure 16 shows a photograph of the electrophoretic gel. 1, 2, and 3 respectively correspond to the original saliva sample (1), and the input liquid (2) and eluate (3) after process electrophoresis. Although some amylase and lactoferrin (1) that were present in the saliva were detected in the eluate (3), most of the amylase and lactoferrin remained in the input chamber (2). In contrast, most of the albumin was able to be transferred to the eluate (3). In this way, it was confirmed that the albumin in the saliva was at least separated from the amylase and lactoferrin.
- Macromolecules or macrocomplexes were present in the saliva sample (1). These macromolecules are presumed to include mucin. In this way, the migration of the macromolecules to the elution chamber could be prevented. For example, the migration of the macromolecules to the elution chamber can be prevented by adjusting the pH of the input chamber. For example, the migration of the macromolecules to the elution chamber can be prevented by using a separator with a relatively narrow mesh structure such as polyacrylamide. These methods may also be combined.
- Lactoferrin has an isoelectric point of 8.8, and at pH 8.5 in the solution of this example, it is slightly positively charged or uncharged. For this reason, it is believed that lactoferrin either migrated in the opposite direction to albumin, or did not migrate at all, or at least did not migrate to the elution chamber.
- the separator may contain a resin that captures small molecules or slows down the migration speed of small molecules (such as a resin used in gel filtration chromatography or size exclusion chromatography, such as Sephacryl (registered trademark)).
- a small molecule capture resin may be mixed into the gel of the separator.
- a gel layer of polyacrylamide gel and a layer containing a small molecule capture resin may be laminated.
- the separator captures not only relatively large molecules such as mucin and lactoferrin, but also small molecule impurities and allows the target substance to pass through. This allows the target substance (e.g., albumin) to be purified.
- Example 10 Separation of albumin and hemoglobin in whole blood
- polyacrylamide gel was used as a separator to separate both albumin and hemoglobin, which were the target substances, from a whole blood sample.
- the electrophoresis buffer was a tris-glycine buffer (pH 5.2, hereafter referred to as 1x "TMG buffer") whose pH had been adjusted with maleic acid. This 1x TMG buffer was introduced into the elution chamber.
- the whole blood sample was prepared as follows: 30 ⁇ L of fingertip blood (whole blood) was collected from the inventor in a blood collection tube, which was mixed with 270 ⁇ L of 1x TMG buffer (containing 0.1% Triton X-100) and left to stand at room temperature for 1 hour. This caused the whole blood sample to be hemolyzed. 300 ⁇ L of this hemolyzed sample was diluted with 11,700 ⁇ L of 1x TMG buffer.
- 1x TMG buffer containing 0.1% Triton X-100
- the separator was prepared as follows. First, 114 ⁇ L of ultrapure water, 20 ⁇ L of 1x TMG buffer pH 5.2, 66 ⁇ L of 30 w/v% acrylamide/bis mixture, 2 ⁇ L of 10% APS, and 0.8 ⁇ L of TMED were mixed to prepare a 10% polyacrylamide gel. 160 ⁇ L of this gel was supported using a CELLLOSE ACETATE ⁇ 0.2 ⁇ m (ADVANTEC) filter unit.
- ADVANTEC CELLLOSE ACETATE ⁇ 0.2 ⁇ m
- Process electrophoresis was performed under cooling at 90V for 20 minutes, then at 80V for 60 minutes, and then at 90V for 20 minutes.
- the measurement electrophoresis was carried out as follows. First, after process electrophoresis, the eluate was removed from the elution chamber, and 15 ⁇ L of the eluate was mixed with 5 ⁇ L of 4x Loading Buffer (Wako, #196-16142). The mixture was heated at 95°C for 10 minutes. 3 ⁇ L of the mixture was dropped onto a 5-20% polyacrylamide gel (DRC, #NTH-576HP10). Electrophoresis was carried out at 180 V for 60 minutes.
- Albumin and hemoglobin move in opposite directions at this pH.
- two elution chambers should be arranged in the direction of the applied voltage relative to the input chamber.
- one elution chamber is provided in the input chamber. Therefore, the method of applying voltage was changed for each of albumin and hemoglobin.
- the direction of voltage application for eluting albumin is referred to as the "forward direction,” and that for hemoglobin is referred to as the "reverse direction.”
- Figure 17 shows a photograph of the electrophoresis gel. 1 to 5 respectively correspond to the original whole blood sample (1), the input liquid (2) and eluate (3) after forward process electrophoresis, and the input liquid (4) and eluate (5) after backward process electrophoresis.
- Electrophoresis unit 18 shows a longitudinal cross-sectional view of an electrophoresis unit 600 according to one embodiment.
- the electrophoresis unit 600 includes, in the longitudinal direction, an electrophoresis tank 651, a top plate 652 covering the electrophoresis tank 651 from above, and a separator 610 disposed in the electrophoresis tank 651.
- An input chamber 601 for accommodating a sample solution and an elution chamber 601 for accommodating an elution solution are defined by the electrophoresis tank 651, the top plate 652, and the separator 610 via the separator 610.
- the volumes of the input chamber 601 and the elution solution or the ratio thereof may be set based on a desired concentration rate.
- the electrophoresis tank 651 may have a circular or U-shaped cross section perpendicular to its length. This allows the electric field to be applied uniformly, reducing waste in the movement of materials. It also allows for a large contact area when contacting a heat sink or fluid (air) for temperature control from the outside.
- the electrophoresis tank 651 may be configured to receive contact with a heat sink, irradiation with electromagnetic waves such as light, or blowing air from the outside. This may allow the temperature of the solution inside to be adjusted.
- the electrophoresis tank 651 may be made of a highly thermally conductive material.
- the electrophoresis tank 651 has electrodes 621, 622 on both end surfaces in the longitudinal direction.
- the electrodes 621, 622 may be fixed to the electrophoresis tank 651.
- the electrodes 621, 622 may be formed of flat metal plates.
- the flat metal plates 621, 622 may be bonded to both end surfaces of the electrophoresis tank 651.
- the electrodes 621, 622 may be formed by depositing a material such as platinum by plating.
- the electrodes 621, 622 may be configured as external members so as to be in contact with or close to both end surfaces of the electrophoresis tank 651 during the electrophoresis process.
- FIG. 19 shows an example of a pipette cartridge 700 including the electrophoresis unit 600 of the above embodiment.
- FIG. 19(A) shows a top view of the pipette cartridge 700
- FIG. 19(B) shows a cross-sectional view taken along line A-A in FIG.
- the pipette cartridge 700 is provided with an electrophoresis unit fixing section 710 for fitting and fixing the electrophoresis unit 600 to a plate (main body) 701.
- the electrophoresis unit fixing section 710 is opened in the plate 701, and the electrophoresis unit 600 is inserted into the opening.
- the electrophoresis unit 600 is fixed by locking pins 711 and 712 fixed to the plate 701 at the four corners of the opening.
- Leaf springs 713, 714 for electrode contact are arranged at both ends of the electrophoresis unit fixing part 710 in the longitudinal direction.
- the electrodes 621, 622 at both ends of the electrophoresis unit 600 inserted and fixed in the opening of the electrophoresis unit fixing part 710 contact the leaf springs 713, 714 for electrode contact, respectively, and an electrical connection is formed between them.
- the leaf springs 713, 714 are connected to connectors 731, 732 fixed to the leading end of the plate 701 in the longitudinal direction via electric wires 733, 734, respectively.
- the connectors 731, 732 abut against a stopper that stops the tip of the pipette cartridge 700 when the pipette cartridge 700 is inserted from its tip into the automatic pipette device body (not shown).
- Contacts (not shown) for the connectors 731, 732 are provided on the end faces. Establishing an electrical connection between the connectors 731, 732 and their contacts allows power to be supplied to the electrophoresis unit 600.
- the electrical connection between the electrophoresis unit 600 and the outside is established by the leaf springs 713, 714 and the connectors 731, 732, but the form of the electrical connection is not limited to this.
- a power supply unit having a leaf spring may be disposed within the main body of the automatic pipette device, and this may move relative to the inserted cartridge 700, with the leaf spring coming into contact with the electrodes 621, 622 at both ends of the electrophoresis unit 600.
- the pipette cartridge may include a well for a measurement, a well for containing a solution required for the measurement, a hole for holding a pipette tip, a tube, etc.
- the pipette cartridge may include a sensor attached.
- the pipette cartridge 700 shown in FIG. 19 includes a sample container holder 721 for placing a container of a sample to be subjected to the electrophoresis process, a sample tip holder 722 for placing a sample tip for taking a sample from a sample container and introducing it into the input chamber of the electrophoresis unit 600, and an elution tip holder 723 for placing an elution tip for taking a solution from the elution chamber after the electrophoresis process.
- the pipette cartridge 700 further includes a buffer well 731 for containing a buffer to be used in the electrophoresis process, and the buffer well 731 is sealed with a sealing membrane 732 until use, sealing off the internal buffer (not shown).
- the sealing membrane is, for example, an aluminum membrane, and the pipette tip can easily penetrate it to obtain the internal buffer.
- the pipette cartridge 700 further includes an elution tube holder 714 for placing a tube for collecting the elution solution after the process.
- the treatment solution after the electrophoresis process can be transferred to the inside of the elution tube, and the tube can be moved from the pipette cartridge 700 to another location.
- the pipette cartridge 700 and/or the automatic pipette device may be configured to control the temperature of the electrophoresis unit 600.
- a temperature-controlled heat sink may be disposed within the automatic pipette device, which may move relative to the inserted cartridge 700 and come into close contact with the electrophoresis tank 651 of the electrophoresis unit 600.
- the automatic pipette device may apply a temperature-controlled fluid (e.g., cooling air) to the surface of the electrophoresis tank 651. These can efficiently and appropriately control the temperature of the solution during the electrophoresis process.
- the temperature of the electrophoresis tank 651 and the temperature of the solution during the electrophoresis process may be measured and automatically controlled.
- a pipette cartridge (unmounted) for mounting an electrophoresis unit may be provided.
- a pipette cartridge (including an electrophoresis unit) may be provided with an electrophoresis unit mounted thereon.
- A001 1 A method for processing a target substance by electrophoresis, comprising: Providing a separator that allows the passage of the target substance; introducing a first solution containing the substance of interest onto a first side of the separator; introducing a second solution to a second side of the separator; and selectively transferring the target substance from the first solution through the separator to the second solution by electrophoresis.
- a method for providing the above. A001b 1.
- a method for processing a target substance by electrophoresis comprising: Providing a separator that allows either the target substance or impurities to pass through; introducing a first solution containing the substance of interest and the contaminants onto a first side of the separator; introducing a second solution to a second side of the separator; and selectively transferring one of the target substance and the contaminants from the first solution through the separator to the second solution by electrophoresis; A method for providing the above.
- A002 A method according to any of the preceding embodiments, comprising: The method for treating the target substance comprises: concentrating said substance of interest; performing at least one of: exchanging a buffer of the substance of interest; and purifying the substance of interest.
- A007 A method according to any one of A001 to A003, or any embodiment thereof, comprising: the separator comprises a material selected from the group consisting of a gel, a semipermeable membrane, and a resin; Method.
- A008 A method according to any one of A001 to A007, or any embodiment thereof, comprising: The separator comprises an agarose gel.
- A012 A method according to A001 or A011, or any of the embodiments, comprising: The method further comprises concentrating the biomolecule. Method.
- A015 A method according to any one of A001 to A012, or any embodiment thereof, comprising: The method further comprises introducing into the second solution a substance (a counter substance) that migrates in a direction opposite to that of the target substance by electrophoresis; selectively transferring the target substance by electrophoresis includes simultaneously transferring the counter substance by electrophoresis from the second solution through the separator to the first solution.
- a substance a counter substance
- the counter substance has an opposite charge to the target substance.
- the counter substance is a polymer.
- the counter substance is a biopolymer.
- the counter substance is a protein or an enzyme.
- the first solvent (first buffer) of the first solution is different from the second solvent (second buffer) of the second solution;
- the separator selectively passes the target substance or allows the target substance to selectively pass therethrough.
- A051 The method according to A031 or A032, or any of the embodiments, comprising: The separator has a semipermeable membrane that selectively allows the target substance to pass through.
- Method. A061 A method according to any one of A001 to A051, or any embodiment thereof, comprising: The separator, the first solution, or the first solution chamber (input chamber) is provided with a selective substance capable of selectively allowing the target substance to pass through the separator and/or inhibiting, preventing, or blocking at least one impurity from passing through the separator. Method.
- A061b A method according to any one of A001b to A051, or any embodiment thereof, comprising: The separator, the first solution, or the first solution chamber (input chamber) is provided with a selective substance capable of selectively allowing at least one impurity to pass through the separator and/or inhibiting, preventing, or blocking the target substance from passing through the separator.
- A062 A method according to any one of A001 to A047, or any embodiment thereof, comprising: further comprising mixing a selectivity substance into the first solution prior to the electrophoresis.
- Method. A063 The method according to A061 or A062, or any of the embodiments, comprising: The selectivity agent has the ability to purify a protein. Method.
- A064 A method according to any one of A061 to A063, or any embodiment thereof, comprising:
- the selective substance or the protein purification resin is selected from the group consisting of hydroxyapatite, a cation exchange carrier, an anion exchange carrier, and a hydrophobic resin.
- Method. A071 A001, or a method according to any of the embodiments, comprising:
- the pH of the first solution is greater (higher)/less (lower) than the isoelectric point of the target substance;
- the target substance has a negative/positive charge
- the selectively moving by electrophoresis comprises applying an electric field such that the first solution side is negative/positive and the second solution side is positive/negative.
- A072 A071 or a method according to any of the embodiments, comprising: The pH of the first solution is equal to or higher than the isoelectric point of at least one of the contaminants contained in the first solution; Method.
- A081 1.
- a method for processing a target substance by electrophoresis comprising: providing a first separator that allows the passage of the target substance; introducing a first solution containing the substance of interest onto a first side of the first separator; introducing a second solution onto a second side of the first separator and onto a first side of a second separator; introducing a third solution onto a second side of the second separator; selectively transferring the target substance from the first solution through the first separator to the second solution by electrophoresis; and transferring the target substance from the second solution through the second separator to the third solution by electrophoresis.
- A081b 1. A method for processing a target substance by electrophoresis, comprising: providing a first separator that allows passage of a first target substance and a second separator that allows passage of a second target substance; introducing a first solution containing the first target substance and the second target substance between the first separator and the second separator; selectively transferring the first target material from the first solution through the first separator to an opposite side of the first separator by electrophoresis; and transferring the second target material from the first solution through the second separator to an opposite side of the second separator by electrophoresis.
- A082 A081b or the method of any embodiment, comprising: The pH of the solution is between the isoelectric point of the first substance of interest and the isoelectric point of the second substance of interest; Method.
- A091 A method according to any one of A001 to A082, or any embodiment thereof, comprising: The first solution contains the target substance and a small molecule impurity having a smaller molecular weight than the target substance,
- the electrophoresis includes repeatedly applying a forward electric field in a direction in which the target substance and the low-molecular-weight impurities pass through the separator and move into the second solution, and applying a reverse electric field.
- Method. A101 A method according to any one of A001 to A081b, or any embodiment thereof, comprising: The first solution is a solution of biological origin.
- Method. A102 A method according to any one of A001 to A081b, or any embodiment thereof, comprising: The first solution is a crude sample.
- A111 A method according to any one of A001 to A103, or any embodiment thereof, comprising: The target substance is a biomolecule contained in the first solution.
- A112 A method according to any one of A001 to A103, or any embodiment thereof, comprising: The target substance is albumin contained in the first solution. Method.
- B001 A device for processing a target substance by electrophoresis comprising: First solution chamber (loading chamber); a second solution chamber (elution chamber) adjacent to the first solution chamber (input chamber); and a separator that separates the first solution chamber from the second solution chamber, allows passage of a target substance from the first solution chamber to the second solution chamber, and has electrical conductivity; Equipped with the first solution chamber is filled with a first solution containing the target substance; the second solution chamber is filled with a second solution; an electric field is applied from outside the first solution chamber and the second solution chamber to selectively migrate the target substance from the first solution chamber through the separator to the second solution chamber by electrophoresis; A device configured to: B001b A device for processing a target substance by electrophoresis, comprising: First solution chamber (loading chamber); a second solution chamber (elution chamber) adjacent to the first solution chamber (input chamber); and a separator that separates the first solution chamber from the second solution chamber, allows passage of either a target substance or impurities from
- the separator has the ability to inhibit, prevent, or block the passage of at least one contaminant; Equipment (device).
- Equipment (device) B041 A device according to any one of the embodiments of B031 or A032, The separator comprises a gel that selectively passes the target substance.
- Equipment (device). B042 B041, or any of the embodiments of the device, The gel is a polyacrylamide gel.
- Equipment (device). B051
- B061 A device according to any one of B001 to B051 or any embodiment thereof, comprising: The separator, the first solution, or the first solution chamber (input chamber) is provided with a selective substance capable of selectively allowing the target substance to pass through the separator and/or suppressing, avoiding, or blocking the passage of at least one impurity through the separator.
- B062 A device according to any one of B031 to B047 or any embodiment thereof, comprising: configured to mix the selectivity substance into a first solution prior to the electrophoresis; Equipment (device).
- B063 The device of any one of B051 or B052 or any of the embodiments,
- the selective material is a protein purification resin; Equipment (device).
- a device for processing a target substance by electrophoresis comprising: First solution chamber (loading chamber); a second solution chamber (first elution chamber) adjacent to the first solution chamber (input chamber); a third solution chamber (second elution chamber) adjacent to the second solution chamber (first elution chamber); a first separator that separates the first solution chamber from the second solution chamber and allows the passage of a target substance from the first solution chamber to the second solution chamber (and has electrical conductivity); and a second separator that separates the second solution chamber from the third solution chamber and allows the passage of the target substance from the second solution chamber to the third solution chamber (and has electrical conductivity);
- An apparatus comprising:
- C001 1 A method for processing a target substance by electrophoresis, comprising: providing an electrophoresis device according to any one of embodiments B001 to B064 or any embodiment; filling the first solution chamber with a first solution containing a substance of interest; filling the second solution chamber with a second solution; and applying an electric field external to the first solution chamber and the second solution chamber to selectively migrate the target substance from the first solution chamber through the separator to the second solution chamber by electrophoresis.
- a method for providing the above. C081 1.
- a method for processing a target substance by electrophoresis comprising: B081, or any of the embodiments, providing an electrophoresis device; filling the first solution chamber with a first solution containing a substance of interest; filling the second solution chamber with a second solution; filling said third solution chamber with a third solution; applying an electric field from outside the first solution chamber and the second solution chamber to selectively move the target substance from the first solution chamber through the first separator to the second solution chamber by electrophoresis; and applying an electric field from outside the second solution chamber and the third solution chamber to move the target substance from the second solution chamber through the second separator to the third solution chamber by electrophoresis; A method for providing the above.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19/150,076 US20260042064A1 (en) | 2023-01-23 | 2024-01-19 | Method and apparatus for treating a target substance by electrophoresis |
| JP2024573017A JPWO2024157889A1 (cg-RX-API-DMAC7.html) | 2023-01-23 | 2024-01-19 | |
| EP24747217.8A EP4657042A1 (en) | 2023-01-23 | 2024-01-19 | Method and apparatus for treating a target substance by electrophoresis |
| CN202480008461.5A CN120604106A (zh) | 2023-01-23 | 2024-01-19 | 通过电泳处理对象物质的方法和装置 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-008270 | 2023-01-23 | ||
| JP2023008270 | 2023-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024157889A1 true WO2024157889A1 (ja) | 2024-08-02 |
Family
ID=91970614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/001427 Ceased WO2024157889A1 (ja) | 2023-01-23 | 2024-01-19 | 電気泳動により対象物質を処理する方法及び装置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20260042064A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4657042A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024157889A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN120604106A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024157889A1 (cg-RX-API-DMAC7.html) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0466118A (ja) * | 1990-07-06 | 1992-03-02 | Nok Corp | 微粒子の製造方法 |
| JP2003230897A (ja) * | 2002-02-08 | 2003-08-19 | Babcock Hitachi Kk | 廃棄物処理方法と装置 |
| JP2009065967A (ja) * | 2007-08-20 | 2009-04-02 | Gunma Univ | 細胞分離装置および細胞分離方法 |
| JP2019138861A (ja) * | 2018-02-15 | 2019-08-22 | 株式会社東芝 | 分析素子及び分析装置 |
| JP2019150016A (ja) * | 2018-02-28 | 2019-09-12 | 国立大学法人富山大学 | 細胞の分離回収装置及び方法 |
| WO2021171794A1 (ja) * | 2020-02-25 | 2021-09-02 | Nok株式会社 | 粒子分離装置 |
-
2024
- 2024-01-19 US US19/150,076 patent/US20260042064A1/en active Pending
- 2024-01-19 WO PCT/JP2024/001427 patent/WO2024157889A1/ja not_active Ceased
- 2024-01-19 EP EP24747217.8A patent/EP4657042A1/en active Pending
- 2024-01-19 CN CN202480008461.5A patent/CN120604106A/zh active Pending
- 2024-01-19 JP JP2024573017A patent/JPWO2024157889A1/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0466118A (ja) * | 1990-07-06 | 1992-03-02 | Nok Corp | 微粒子の製造方法 |
| JP2003230897A (ja) * | 2002-02-08 | 2003-08-19 | Babcock Hitachi Kk | 廃棄物処理方法と装置 |
| JP2009065967A (ja) * | 2007-08-20 | 2009-04-02 | Gunma Univ | 細胞分離装置および細胞分離方法 |
| JP2019138861A (ja) * | 2018-02-15 | 2019-08-22 | 株式会社東芝 | 分析素子及び分析装置 |
| JP2019150016A (ja) * | 2018-02-28 | 2019-09-12 | 国立大学法人富山大学 | 細胞の分離回収装置及び方法 |
| WO2021171794A1 (ja) * | 2020-02-25 | 2021-09-02 | Nok株式会社 | 粒子分離装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260042064A1 (en) | 2026-02-12 |
| CN120604106A (zh) | 2025-09-05 |
| EP4657042A1 (en) | 2025-12-03 |
| JPWO2024157889A1 (cg-RX-API-DMAC7.html) | 2024-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0287513B1 (en) | An isoelectric focusing process and a means for carrying out said process | |
| Grimshaw et al. | Dynamic membranes for protein transport: chemical and electrical control | |
| AU2006224893B2 (en) | Electrofiltration method | |
| CN101512334A (zh) | 用电泳来分离和去除某些蛋白和颗粒的方法与装置 | |
| AU764951B2 (en) | Small separation apparatus | |
| US20080067079A1 (en) | Method of Analyzing Sample and Analyzing Apparatus | |
| US7309428B2 (en) | Apparatus for separating components from blood plasma | |
| KR20150023331A (ko) | 음으로 대전된 입자들로의 폴리뉴클레오티드들의 크로마토그래피 정제 | |
| US7250100B2 (en) | Two dimensional electrophoresis cassette | |
| US20260042064A1 (en) | Method and apparatus for treating a target substance by electrophoresis | |
| EP1217367A1 (en) | Radial electrophoresis apparatus and method | |
| EP1294472B1 (en) | Electrophoresis separation and treatment of samples | |
| JPWO2004048398A1 (ja) | 核酸の濃縮精製方法および装置 | |
| Weber et al. | Counterbalancing hydrodynamic sample distortion effects increases resolution of free‐flow zone electrophoresis | |
| US20090314639A1 (en) | Means and devices for electro-filtration of molecules | |
| EP1661906B1 (en) | Method of preparing solution for proteomic analysis | |
| CA2429266A1 (en) | Isoelectric gateways and method and apparatus for using such isoelectric gateways | |
| JPWO2024157889A5 (cg-RX-API-DMAC7.html) | ||
| AU2004200567B2 (en) | Blood-Related Dialysis and Treatment | |
| JP2011002238A (ja) | 相転移電気泳動方法及び装置 | |
| Krajewski | Gel-purification from micro-to macro quantities of biopolymers | |
| JPS5926105A (ja) | 両性電解質の分離精製装置 | |
| WO2003070360A1 (en) | Low volume separation apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24747217 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2024573017 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024573017 Country of ref document: JP Ref document number: 202480008461.5 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202517074493 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 202517074493 Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 202480008461.5 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2024747217 Country of ref document: EP |